Condition
Healthy Volunteers
Cardiometabolic Diseases
Locations
Netherlands
Start date
02/09/2026
Identifiers
Trial ID NN6708-8540,
NCT number NCT07797855,
Eudract number Not Available
NCT number NCT07797855,
Eudract number Not Available
Summary
This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, target engagement, and metabolism of NNC0705-0002 after single and multiple doses in healthy adults. NNC0705-0002 or a placebo (a substance that looks like the study medicine but contains no active medicine), and the treatment they receive may be chosen by chance. NNC0705-0002 is a new medicine that is not yet approved for doctors to prescribe. Depending on the part of the study, participation may last for up to about 7 weeks, including screening, treatment, and follow-up visits.
Trial Overview:
Treatment
DRUG: NNC0705-0002
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Sep 02 2026 - Aug 01 2027
Participants
112
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 55 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.